Gastrointestinal Cancers

The Food and Drug Administration revised the existing approval of Keytruda, Herceptin and chemotherapy for patients with unresetable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

The Food and Drug Administration approved Keytruda plus chemotherapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

The combination of Lumakras and Vectibix led to better progression-free survival compared with standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

A phase 1 trial is being conducted to evaluate the combination of PT886 and Keytruda in patients with claudin 18.2 positive gastric or gastroesophageal junction (GEJ) adenocarcinomas.

Interim findings from the phase 2 ASPEN-06 clinical trial show evorpacept’s potential for treatment of patients with HER2-positive gastric/gastroesophageal junction cancer.

Adding debulking surgery to chemotherapy did not cause a significant decrease in health-related quality of life for patients with metastatic colorectal cancer, research showed.

Findings from the CheckMate 649 trial “further support the use of (Opdivo) plus chemotherapy as a tolerable and efficacious first-line treatment” for some patients, according to researchers.

Battling the unforgiving foe: Cancer.

Treatment combination of Lutathera and Sandostatin improved outcomes for patients with gastroenteropancreatic neuroendocrine tumors.

Treatment of Opdivo and Stivarga plus chemotherapy improves survival in patients with advanced esophageal adenocarcinoma and certain esophageal and stomach cancers.

The second phase of a study evaluating androgen receptor inhibitor masofaniten combined with antiandrogen Xtandi for the treatment of patients with metastatic castration-resistant prostate cancer has been launched.

Vitamin D supplements have been shown to reduce the risk of relapse or death in patients with digestive tract cancer.

A new finding can help predict whether patients with advanced colorectal cancer can benefit from receiving immunotherapy.

At first, I thought I had hemorrhoids, but ended up eventually being diagnosed with anal cancer.

Here’s a look back at the therapies for solid cancers that gained FDA approval this summer.

A phase 3 trial shows that zolbetuximab improved survival in patients with advanced gastric or gastroesophageal junction cancer.

A majority of women with a history of colorectal cancer experience long-term gastrointestinal symptoms, which may be associated with psychological distress, according to recent research.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Larger liver resections do not always improve survival in patients with gallbladder cancer, recent research showed.

Fruquintinib improved overall survival compared with placebo in patients with refractory metastatic colorectal cancer.

If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Patients with advanced cancers who live in states that expanded Medicaid were more likely to receive early palliative care, although utilization remains low in the U.S.

Patients 60 years and older with gastrointestinal cancers who reported inadequate emotional support were more likely to have poorer physical and mental quality of life, although no effect was observed in overall survival.

From country music star, Toby Keith, providing an update on his cancer to the Duchess of York announcing her diagnosis, here’s what’s happening in the oncology space this week.

Taking five or more medications increased the risk of death, hospitalizations and ER visits in elderly patients with colorectal cancer.

Treatment with a CAR-M cell therapy plus Keytruda is being assessed in a phase 1 study in patients with HER2-overexpressed tumors.

Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.